BM201

BM201 is a small molecule drug under development as an immunostimulant cancer therapy. It acts as an agonist of Toll-like receptor 7 (TLR7) and Toll-like receptor 8 (TLR8), stimulating the innate immune system to enhance anti-tumor responses. The drug is being investigated primarily for use in combination with radiotherapy in patients with advanced or metastatic solid tumors who have failed standard therapies or are not eligible for them. Clinical trials are ongoing in China, with the highest phase reached being Phase 1 for oncology indications such as advanced malignant solid neoplasms and sarcoma[2][4][6][7]. The developer is InnoBM Pharmaceuticals, and other organizations involved include Suzhou Baimai Biopharmaceutical Co. Ltd., Zhongshan Union Weihua Pharmaceutical Co. Ltd., and Beijing Puqi Pharmaceutical Technology Co Ltd.[2][4][5][7].